Document:

Termination Agreement Re Biologics Distribution Agreement

 Exhibit 10.1 
 TERMINATION AGREEMENT RE BIOLOGICS DISTRIBUTION AGREEMENT 
 This “Termination Agreement Re
Biologics Distribution Agreement” (this “Agreement”) is executed as of this 22nd day of August, 2007 by and between McKESSON CORPORATION, a Delaware corporation (“McKesson”) and ACCENTIA BIOPHARMACEUTICALS, INC., a Florida
corporation (“Accentia”) based on the following facts and understandings: 
 RECITALS 
 A. McKesson and Accentia are parties to that certain “Biologics Distribution Agreement” (the “BDA”) dated as of February 27,
2004. 
 B. Pursuant to the BDA, Accentia is indebted to McKesson for certain unliquidated payment obligations that currently exceed
$3,000,000. 
 C. All obligations of Accentia under the BDA, including the payment obligations, are secured and/or guaranteed by the
following (among other things): 
 i. All of Accentia’s personal
property, wherever located and whether now existing or owned or hereafter acquired or arising, including all accounts, chattel paper, commercial tort claims, deposit accounts, documents, equipment (including all fixtures), general intangibles,
intellectual property, patents, trademarks, service marks, trade names, trade secrets, customer lists, copyrights, payment intangibles, instruments, inventory, investment property (including but not limited to all stock it holds in Teamm
Pharmaceuticals, Inc. and The Analytica Group, Inc. and Biovest Inc.,1 called the “Subsidiary Stock”), membership interests, letter-of-credit
rights, money and all products, proceeds and supporting obligations of any and all of the foregoing (the “Accentia Collateral”); 
 ii. Certain shares of capital stock in BioDelivery Sciences International, Inc. (the “BDSI Stock”) and in Star Scientific, Inc. (the “SSI Stock”) owned by either Regent Court Technologies (a
limited liability company of which Francis E. O’Donnell, Jr., M.D. is the managing member and which is referred to as “RCT”) or Hopkins Capital Group II, LLC (a limited liability company of which Francis E. O’Donnell, Jr., M.D.
is a manager and which is referred to as “HCG II”), as more fully described on Exhibit A attached hereto (the “Stock Pledged by O’Donnell Entities”); 

	 1
	 Pursuant to that certain “Eighth Modification of First Amendment”
executed by Accentia and McKesson on or about September 28, 2006, McKesson agreed to release its lien on and security interest in 18,000,000 shares of Biovest common stock owned by Accentia and represented by certificates numbered B12066 and
B10118 subject to certain terms and conditions. 

 iii. That certain “Principal Guaranty” dated as of November 30, 1998 and
executed by Francis E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. in favor of McKesson, and reaffirmed from time to time; and 
 iv. A “New Subsidiary Guaranty” executed by Teamm Pharmaceuticals, Inc. (“Teamm”) and The Analytica Group, Inc. (“Analytica”), two wholly-owned subsidiaries of Accentia, executed in favor
of McKesson, the obligations pursuant to which New Subsidiary Guaranty were secured by all personal property of Teamm and/or Analytica pursuant to the terms of that certain security agreement (the “New Subsidiary Security Agreement”)
executed by Teamm and Analytica in favor of McKesson. 
 D. McKesson has not made a written notice of termination under the BDA, however,
Accentia has proposed to McKesson that McKesson agree to (i) convert the indebtedness owing by Accentia to McKesson under the BDA into $4,000,000 worth of Accentia common stock valued at the greater of $2.67 per share or the volume weighted
average closing price per share 5 calendar days before closing of the conversion transaction; (ii) terminate the BDA for no consideration other than the consideration included in Accentia’s proposal to McKesson; (iii) release Francis
E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. from their respective obligations under the Principal Guaranty; and (iv) release its liens upon and security interests in the BDSI Stock and the SSI Stock. 
 E. McKesson is willing to enter into an agreement that results in a conversion of the payment obligations owing under the BDA being converted to common
stock of Accentia, but only on the terms and conditions set forth in this Agreement. 
 AGREEMENT 
 NOW THEREFORE, for fair and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto enter into the
following Agreement: 
 1. Agreement of McKesson. Effective upon the date that all conditions precedent to McKesson’s obligations
hereunder are satisfied (the “Closing Date”), McKesson agrees to: 
 a. Convert the outstanding payment obligations
owing under the BDA into that number of shares of common stock in Accentia (the “Converted Stock”) that is equal to $4,000,000 divided by the greater of (a) $2.67, and (b) the weighted average closing price for Accentia common
stock as listed on the New York Stock Exchange on the date that is five (5) calendar days before the Closing Date, provided that any fractional amounts shall be deemed rounded up to get a full additional share (i.e., $4,000,000 ÷
$2.67 = 1,498,127.3 but would result in a conversion into 1,498,128 shares of Accentia common stock); 
  

 2 

 b. Terminate the BDA; 
 c. Release Francis E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. from their respective obligations under the Principal Guaranty,
and execute and deliver to Accentia (at the sole expense of Accentia, Francis E. O’Donnell, Jr., M.D. and/or Dennis L. Ryll, M.D.) all documents necessary to evidence such release of liability under the Principal Guaranty; 
 d. Release each of the following from their respective obligations under any guaranty or third party pledge agreement executed by any of
them in favor of McKesson which guaranties or secures the obligations owed by Accentia to McKesson and deliver to Accentia (at the sole expense of Accentia or such guarantor or third party pledgor) all documents necessary to evidence such release:

 i. Francis E. O’Donnell, Jr., M.D.; 
 ii. Dennis L. Ryll, M.D.; 
 iii. Regent Court Technologies; 
 iv. Hopkins Capital Group LLC; 
 v. Hopkins Capital Group II, LLC; and/or 
 vi. MOAB Investments, LP; and 
 e. Release its lien on and security interest in the BDSI
Stock, the SSI Stock, and any of the other Stock Pledged by O’Donnell Entities listed on Exhibit A attached hereto and deliver to Accentia (at the sole expense of Accentia or the applicable guarantor or third party pledgor) all documents
necessary to evidence such release, as well as to (i) deliver all stock certificates in the custody or control of McKesson to the applicable guarantor or third party pledgor, and (ii) terminate all control agreements relating to such
stock, in each case at the sole expense of Accentia or the applicable guarantor or third party pledgor; and (iii) terminate any UCC filings related to the released collateral, in each case under (i), (ii) and/or (iii) at the sole
expense of Accentia or the applicable guarantor or third party pledgor. 
 2. Conditions Precedent. It shall be a condition precedent
to each and every obligation of McKesson hereunder that each of the following events shall have occurred unless waived in writing by McKesson: 
 a. McKesson shall have received an original counterpart of this Agreement, duly executed by Accentia and enforceable by McKesson; 
  

 3 

 b. McKesson shall have received original counterparts of the “Consent to Agreement,
Reaffirmation and Release Agreement” in the form of Exhibit B attached hereto (the “Guarantor & Affiliate Consent”), duly executed by each of the entities listed in the signature blocks on said Exhibit B and
enforceable by McKesson; 
 c. Any and all consents as may be necessary or appropriate to the enforceability of (i) this
Agreement by McKesson against Accentia, or (ii) the Guarantor Consent by McKesson against any of the persons or entities a party thereto, shall have been duly executed and delivered to McKesson, including any consent as may be required by
contract or applicable law to be given to Accentia by Midsummer Investment, Ltd., Laurus Master Fund, Ltd., or any shareholder of Accentia; 
 d. An opinion of counsel for Accentia stating that each of the foregoing conditions precedent has been satisfied; and 
 e. Payment to McKesson of all attorneys’ fees and costs associated with negotiating and documenting this Agreement and the documents executed pursuant hereto, and payment of any and all outstanding fees, costs
and expenses as Accentia may owe to McKesson under any or all of its agreements with McKesson. 
 3. Obligation of Accentia to Register
Converted Stock. On or before the date that is 120 days after the Closing Date (the “Registration Deadline”), Accentia shall have accomplished one or more of the following steps (each a “Saleability Step”): 
 a. Registered the Converted Stock under the Securities Act of 1933 such that McKesson may sell some or all of the Converted Stock to the
public at large, as and when McKesson may choose to do so without restriction, 
 b. Delivered to McKesson (i) stock
certificates on account of all of the original Converted Stock (i.e., excluding the Additional Stock otherwise included in the definition of “Converted Stock”) without any legend restricting the transfer or re-sale of said shares into the
public market pursuant to Rule 144K promulgated under the Securities Act of 1933 (the “Securities Act”) whereby McKesson will be able to sell said shares as freely as if covered by an effective registration statement, and (ii) a legal
opinion of qualified securities counsel that the Saleability Step described in this Paragraph 3(b) has been completed (at the expense of Accentia) and stating that the Converted Stock is as saleable to the public as though it had been registered as
required by Paragraph 3(a) above, provided that, if McKesson is holding any Additional Stock at the time this Saleability Step is completed, Accentia agrees that it will deliver to McKesson stock certificates on account of such Additional Stock
without any legend restricting the transfer or re-sale of said shares into the public market pursuant to Rule 144K promulgated under the Securities Act within five (5) business days of the date when the applicable holding periods under Rule
144K as to such stock have passed, or 
  

 4 

 c. Purchased the Converted Stock from McKesson in accordance with the provisions of
Paragraph 5(b) below. 
 If Accentia fails to complete one or more of the Saleability Steps with regard to all of the Converted Stock on or before the
Registration Deadline, then on the first day after the Registration Deadline, and on the first day after each 30-day period that follows the first day after the Registration Deadline during which no Saleability Step has been completed, Accentia
shall deliver to McKesson an additional number of shares of Accentia common stock (collectively, the “Additional Stock”) in accordance with the following schedule: 
 i. On the first day after the Registration Deadline, Accentia shall issue and/or deliver to McKesson that number of additional shares in
Accentia that is determined by dividing $25,000 by $2.67, provided that all fractional shares shall be rounded up to the next whole share; 
 ii. If Accentia has still not completed one or more of the Saleability Steps on the date that is 30 days after the Registration Deadline, then on the date that is 31 days after the Registration Deadline, Accentia
shall issue and/or deliver to McKesson that number of additional shares in Accentia that is determined by dividing $50,000 by $2.67, provided that all fractional shares shall be rounded up to the next whole share; 
 iii. If Accentia has still not completed one or more of the Saleability Steps on the date that is 60 days after the Registration Deadline,
then on the date that is 61 days after the Registration Deadline, Accentia shall issue and/or deliver to McKesson that number of additional shares in Accentia that is determined by dividing $100,000 by $2.67, provided that all fractional shares
shall be rounded up to the next whole share; 
 iv. If Accentia has still not completed one or more of the Saleability Steps
on the date that is 90 days after the Registration Deadline, then on the date that is 91 days after the Registration Deadline and on each date that is 30 days after the previous date when Additional Stock is to be issued to Accentia as set forth
in this Paragraph 3(iv) or portion thereof if no Saleability Step occurs as of the first anniversary of the Closing Date, Accentia shall issue and/or deliver to McKesson Additional Stock calculated on each such date that is determined by
dividing $100,000 by $2.67, provided that all fractional shares shall be rounded up to the next whole share, and provided that this provision shall apply up until the date that is the first anniversary of the Closing Date. In other words, if as of
the first anniversary of the Closing Date no Saleability Steps have been completed by Accentia and all Additional Sock is calculated by reference to a share price of $2.67 per share, Accentia will have delivered to McKesson Additional Stock as set
forth on Exhibit C attached hereto), provided that all fractional shares shall be rounded up to the next whole share. 
  

 5 

 Each dollar amount used to calculate the number of shares of Additional Stock to be issued and delivered to McKesson as
described in the foregoing subparagraphs 3(i) through 3(iv) is referred to herein as the “Defined Dollar Equivalent” of such stock. Except as may otherwise be explicitly stated in this Agreement, any and all Additional Stock that is
delivered or required to be delivered to McKesson after the Registration Deadline due to the failure of Accentia to timely complete at least one Saleability Step shall be deemed included in the definition of “Converted Stock” such that the
original Converted Stock and all Additional Stock must be included in the applicable Saleability Step by the next applicable deadline to complete a Saleability Step with regard to the “Converted Stock,” and such that any rights or
obligations that relate to the Converted Stock at any given time shall apply to all the Converted Stock and all the Additional Stock issued and delivered (or required to be issued and delivered) to McKesson as of such date. Furthermore, if Accentia
relies on its having completed the Saleability Step described in Paragraph 3(b) above, and it turns out that any of the Converted Stock that the opinion described in paragraph 3(b) states was readily saleable under Rule 144K of the Securities Act
was not in fact “as saleable to the public as though it had been registered as required by Paragraph 3(a) above,” then that Saleability Step under Paragraph 3(b) shall be deemed to have never occurred and all rights to Additional Stock
(and all increases in the Guaranteed Return described below) will be deemed to have accrued to the benefit of McKesson retroactively as though no Saleability Step under Paragraph 3(b) had ever been claimed to have occurred. Furthermore, Accentia
shall indemnify and hold McKesson harmless from all costs, liabilities, fines or expenses (including attorneys’ fees and costs) as McKesson may incur if McKesson sells any of the Converted Stock (or Additional Stock as to which applicable
holding periods under Rule 144K have passed) in reliance on the delivery to McKesson of the items described in Paragraph 3(b) which led McKesson to believe (whether reasonably or unreasonably) that the requirements of Rule 144 were satisfied and/or
that the Converted Stock and the Additional Stock as to which the relevant holding periods had passed were as readily saleable to the public by McKesson as though such stock had been registered, and that turns out not to have been the case.

  

 6 

 4. Guaranteed Return. As an inducement to McKesson to convert the payment obligations under the
BDA into equity on the terms and conditions set forth in this Agreement, Accentia hereby guarantees to McKesson that by the date that is the first anniversary of the Closing Date, McKesson will receive proceeds from the disposition of the Converted
Stock (which term includes all Additional Stock issued or required to be issued to McKesson under this Agreement) equal to the “Guaranteed Return” described below. This guaranty shall be effectuated through the “Put” right
described below, but it is a guaranty. The amount of the “Guaranteed Return” is as follows: 
 a. On the Closing
Date, the amount of the “Guaranteed Return” for the Converted Stock shall be $4,000,000. 
 b. Each time that
Additional Stock is delivered to McKesson or is required to be delivered to McKesson pursuant to the provisions of Paragraph 3 thereof due to the continued failure of Accentia to complete a Saleability Step in a particular time frame as set forth in
this Agreement, the “Guaranteed Return” shall increase by an amount equal to the “Defined Dollar Equivalent” used to calculate the amount of Additional Stock issued and delivered (or required to be issued and delivered) to
McKesson as of such date. 
 Using the example set forth on Exhibit C, on the first anniversary of the Closing Date if no Saleability Steps have been
completed by Accentia, the Guaranteed Return would be $4,000,000 plus $875,000. If on the other hand, a Saleability Step with regard to the Converted Stock is completed by the date that is 140 days after the Closing Date (i.e., 20 days
after the Registration Deadline), the Guaranteed Return on the first anniversary of the Closing Date would be $4,000,000 plus $25,000. In addition, if the Saleability Step that is ultimately completed by Accentia (if any) is the
Saleability Step described in Paragraph 3(b), and if at the time such Saleability Step is completed McKesson is holding Additional Stock that would have been readily saleable to the public as represented in the opinion delivered to McKesson pursuant
to said Paragraph 3(b) but for the fact that the Additional Stock has not been held by McKesson for the applicable holding period under applicable law, the fact that the Additional Stock though issued may or may not be saleable to the public at the
time will not reduce the amount of the Guaranteed Return that McKesson is entitled to on the first anniversary of the Closing Date. 
  

 7 

 5. Put and Call Rights. 
 c. Put. If on the first anniversary of the Closing Date, McKesson has not realized gross proceeds from the disposition of the
Converted Stock (which term includes all Additional Stock issued and delivered or required to be issued and delivered to McKesson as of such date) at least equal to the Guaranteed Return defined in Paragraph 4 above with respect to all such stock
(including any stock that may as yet not be readily saleable), McKesson shall have the right to demand from Accentia at any time thereafter the immediate payment of the difference between the Guaranteed Return then applicable and the actual gross
cash proceeds received by McKesson from the disposition of the Converted Stock (which term includes all Additional Stock issued and delivered or required to be issued and delivered to McKesson as of such date) in exchange for which McKesson shall
immediately transfer and deliver to Accentia any remaining Converted Stock (which term includes all Additional Stock issued and delivered or required to be issued and delivered to McKesson) that McKesson still owns, though it shall not be required
that McKesson own any Converted Stock in order to exercise its rights under this Paragraph 5(a). Immediate payment shall mean payment within three (3) business days of demand by McKesson, which demand shall be in writing and may be mailed,
emailed or sent by facsimile to: 
 Accentia Biopharmaceuticals, Inc. 
 324 S. Hyde Park Avenue 
 Suite 350

 Tampa FL 33606 
 Attn: Alan
Pearce 
 Fax: 813-287-6642 
 email: alan.pearce@comcast.net 
 Within three (3) business days after receiving good funds from Accentia on account of
the Guaranteed Return as set forth herein, McKesson shall deliver any remaining Converted Stock in its possession or control to Accentia at the foregoing address. 
 d. Call. Accentia shall have the right upon 10 days’ written notice to McKesson to purchase all (but not less than all) of the
Converted Stock (which term includes any Additional Stock issued or required to be issued to McKesson) still held by McKesson as of the date that is 10 days after such notice is received by McKesson (the “Call Date”) for a price determined
as set forth below: 
 (i) If as of the date that Accentia sends its notice to McKesson of its desire to purchase the
Converted Stock still held by Accentia, Accentia has not registered the Converted Stock under the Securities Act of 1933 nor completed any other Saleability Step, then the price that Accentia must pay to McKesson for the Converted
Stock shall be equal to the amount of the Guaranteed Return calculated as of the Call Date and without regard to any Saleability Step that may intervene between the sending of notice and the Call Date; and 
  

 8 

 (ii) If as of the date that Accentia sends its notice to McKesson of its desire to
purchase the Converted Stock still held by McKesson, Accentia has completed a Saleability Step under this Agreement, then the price that Accentia must pay to McKesson for any Converted Stock (which term includes any Additional Stock held by
McKesson) shall be equal to the greater of (a) the Guaranteed Return in effect as of the Call Date less any actual proceeds from the disposition of any portion of the Converted Stock (which term includes any Additional Stock held by McKesson)
received by McKesson prior to the Call Date, and (b) the weighted average closing price for Accentia common stock as listed on the New York Stock Exchange on the date that is five (5) calendar days before the Call Date multiplied by the
number of shares of Converted Stock (which term includes any Additional Stock held by McKesson) still held by McKesson as of the Call Date. 
 After receiving notice from Accentia of Accentia’s desire to purchase the Converted Stock as described in this Paragraph 5, McKesson shall have no obligation to restrict itself from selling or disposing of the Converted Stock (which
term includes any Additional Stock held by McKesson) before the Call Date except as may be imposed by applicable law other than this Agreement. 
 6. Continued Effectiveness of Security Agreements and Guaranties. Except as explicitly set forth in this Agreement, all security agreements and guaranties executed by Accentia in favor of McKesson shall remain in full force and
effect excepting only that the term “Obligations” shall be deemed modified to consist of (a) the obligations of Accentia to McKesson under this Agreement, (b) all obligations of Accentia under any security agreement or guaranty
executed by Accentia in favor of McKesson to (i) protect, preserve and/or not commit waste with respect to the collateral described therein (the “Accentia Collateral”), and (ii) indemnify McKesson for fees, costs, losses and
liabilities required to be paid by Accentia thereunder. 
 7. Release. In further consideration of McKesson’s willingness to
enter into this Agreement, and as a material inducement to McKesson to do so, Accentia hereby forever releases and discharges McKesson and its predecessors-in-interest, and their respective officers, directors, shareholders, employees, agents,
attorneys, advisors, and successors-in-interest from any and all claims, demands, controversies, actions, causes of action, obligations, liabilities, expenses, costs, attorneys’ fees and damages of any nature or character, or any
kind, at law or in equity, past, present, or future, known or unknown, suspected or unsuspected, now owned or hereafter acquired, arising out of or relating in any way to Accentia, American Prescription Providers, Inc., American Prescription
Providers of New York, Inc., American Prescription Providers of Pennsylvania, Inc., Accent Rx, Inc., Teamm Pharmaceuticals, Inc., The Analytica Group, Inc., BioVest Inc., Regent Court Technologies, Hopkins Capital Group, LLC, Hopkins Capital Group
II, LLC, Moab Investments, LP, Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., any affiliates of any of the foregoing, any and all obligations of any of the foregoing persons and entities (or their affiliates) owing to McKesson or to any
other person or entity, or any other matter whatsoever, save and except only McKesson’s obligations to be performed after the date hereof under Agreement. It is the intention of Accentia that the 

  

 9 

 
foregoing release shall be effective as a bar to all actions, fees, damages, losses, claims, liabilities, demands or debts whatsoever, of any kind or nature,
known or unknown, suspected or unsuspected. Accentia expressly waives any and all rights and benefits conferred upon it by virtue of California Code of Civil Procedure section 1542 (or any similar law) which provides as follows: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE,
WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
 Accentia expressly acknowledges that McKesson has separately
bargained for the foregoing waiver of the provisions of California Code of Civil Procedure section 1542 and has been advised by its own counsel of the full legal consequences of this release and waiver. 
 8. Termination of BDA. Effective upon the satisfaction of all conditions precedent to the obligations of McKesson under this Agreement, McKesson
agrees (as does Accentia) that the BDA will have been terminated and all obligations of Accentia to McKesson and all obligations of McKesson to Accentia (if any) have been terminated and incorporated into this Agreement, excepting only any
obligations relating to the protection of confidential information (if any), which obligations to protect confidential information shall survive termination of the BDA. Furthermore, effective upon the satisfaction of all conditions precedent to the
obligations of McKesson under this Agreement, McKesson agrees Accentia has been released and discharged from any further obligations under the BDA, all such obligations having been amended, restated and incorporated into this Agreement. 

9. Miscellaneous. 
 a. Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of California. 
 b. Entire Agreement: Agreement. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and the Assumption Agreement and other Documents shall not be further
amended except by the written agreement of the parties. 
  

 10 

 c. Fees. Accentia agrees to pay on demand (i) the out-of-pocket costs and
expenses of McKesson and the fees and disbursements of counsel to McKesson (including allocated costs and expenses of internal legal services), in connection with the negotiation, preparation, execution and delivery of this Agreement, and any other
agreements executed in connection herewith or pursuant hereto including the Consent and any termination or release documents requested by Accentia and which McKesson has agreed to provide; and (ii) all costs and expenses of McKesson and fees
and disbursements of counsel (including allocated costs and expenses for internal legal services), in connection with any amendments, modifications or waivers of the terms of this Agreement, any default, the enforcement or attempted enforcement of,
and preservation of any rights or interests under this Agreement, including any fees incurred n connection with any bankruptcy proceeding of Accentia or any of its affiliates. 
 d. Acknowledgement. In granting the accommodations set forth in this Agreement, McKesson is not establishing (and has not
established) a pattern and practice or course of dealing of (i) granting accommodations requested by Accentia or any other person or entity, (ii) terminating agreements which it has the full power and authority to enforce, such as the BDA,
nor (iii) release collateral or guarantors from their obligations under duly executed guaranties. Except as expressly set forth in this Agreement or in another writing signed by McKesson, each and all of the agreements between McKesson and
Accentia (and any other person or entity) remains in full force and effect in accordance with their express written terms. 
 e. Time. Time is of the essence of each term of this Agreement. 
 f. Third Party Beneficiaries. There
are no third party beneficiaries of this Agreement. 
 g. Counterparts. This Agreement may be executed in any number of
counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. 
 [Signatures on next page.] 
  

 11 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date first above
written. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Alan Pearce

	Title:	 	 CFO

	
	Accentia Biopharmaceuticals, Inc.
	324 S. Hyde Park Avenue
	Suite 350
	Tampa FL 33606
	Attn:	 	Alan Pearce
	Fax:	 	813-287-6642
	email:	 	alan.pearce@comcast.net
	
	McKESSON CORPORATION
		
	By:	 	 /s/ Ana Schrank

		 	Ana Schrank
	Title:	 	VP Financial Services
	
	McKesson Corporation
	One Post Street
	San Francisco, CA 94104
	Attn:	 	Ms. Ana Schrank
	Fax:	 	(415) 732-2967
	email:	 	ana.schrank@mckesson.com

  

 12 

 EXHIBIT A 
 Stock Pledged by O’Donnell Entities 
  

	1.	2,000,000 shares of BioDelivery Sciences International, Inc (BDSI) (Held in account # 676-40010-19 at Smith Barney/Citigroup in the name of Hopkins Capital Group II, LLC. These
shares are subject to a Control Agreement to be terminated.) 

  

	2.	1,000,000 shares of Star Scientific International, Inc (STSI) stock represented by certificate #12445 and owned by Regent Court Technology (Physically held by McKesson Corporation
and to be returned to Regent Court Technology or its representative as directed by Accentia.) 

  

	3.	All shares of Accentia Biopharmaceuticals, Inc (ABPI) that were pledged to McKesson. 

  

 13 

 EXHIBIT B 
 Consent to Agreement, Reaffirmation and Release Agreement 
 This “Consent to Agreement,
Reaffirmation and Release Agreement” is hereby executed by the undersigned parties as of this      day of August, 2007 as a condition to the obligations of McKesson Corporation (“McKesson”)
under that certain “Termination and Debt Conversion Agreement” dated as of the date hereof (the “Agreement”) and executed by and between McKesson and Accentia Biopharmaceuticals, Inc.(“Accentia”). Each of the
undersigned persons and entities, as a material inducement to McKesson to enter into the Agreement hereby confirms, acknowledges and agrees in favor of McKesson that: 
 (a) it or he has read the Agreement and consents to its terms, including without limitation the conversion by McKesson of the indebtedness owed to McKesson under the BDA into equity on the terms and conditions set
forth in the Agreement, the release of the liens and security interests in the BDSI Stock and the SSI Stock, and the release of Francis E. O’Donnell, Jr., M.D and Dennis L. Ryll, M.D. from their respective obligations under the Principal
Guaranty; 
 (b) it or he acknowledges and agrees that each of the Recitals set forth in the Agreement is true and correct and binding upon
such undersigned person or entity; 
 (c) each guaranty, third party pledge agreement, security agreement or other agreement signed by any of
the undersigned persons or entities in favor of McKesson or any affiliate of McKesson (as such documents may have been amended in writing from time to time) remains in full force and effect and each is enforceable in accordance with its express
written terms, except as explicitly provided in the Agreement and only as explicitly provided in the Agreement, and provided that that the obligations secured or guarantied pursuant to such guaranty, third party pledge
agreement, security agreement or other agreement shall include the obligations of Accentia to McKesson under this Agreement. By way of example and not as a limitation, the New Subsidiary Guaranty executed by Teamm Pharmaceuticals, Inc.
(“Teamm”) and The Analytica Group, Inc. (“Analytica”) shall remain (and Teamm and Analytica agree it does remain) in full force and effect as to any obligations of Accentia to McKesson including under the Agreement, and likewise
the New Subsidiary Security Agreement encumbering all personal property of Teamm and/or Analytica continues to secure the New Subsidiary Guaranty, notwithstanding that the obligations guaranteed thereunder now include the obligations of Accentia
under the Agreement; and 
 (d) none of the undersigned persons or entities has any known or unknown defenses, counterclaims, rights of
offset, set off, or recoupment, or any other causes of action against McKesson or any person or entity that would prevent or interfere with the full collection and enforcement by McKesson of their respective obligations to McKesson, including but
not limited to any guaranty, third party pledge agreement, or security agreement signed by any or each of them in favor of McKesson, except to the extent the same has expressly been discharged, released or terminated in a writing signed by McKesson.

  

 14 

 In further consideration of McKesson’s willingness to enter into the Agreement, and as a material
inducement to McKesson to do so, each of the undersigned persons or entities (collectively, the “Releasing Parties”) hereby forever releases and discharges McKesson and its predecessors-in-interest, and their respective officers,
directors, shareholders, employees, agents, attorneys, advisors, and successors-in-interest (the “Released Parties”) from any and all claims, demands, controversies, actions, causes of action, obligations, liabilities, expenses, costs,
attorneys’ fees and damages of any nature or character, or any kind, at law or in equity, past, present, or future, known or unknown, suspected or unsuspected, now owned or hereafter acquired, arising out of or relating in any way to Accentia,
American Prescription Providers, Inc., American Prescription Providers of New York, Inc., American Prescription Providers of Pennsylvania, Inc., Accent Rx, Inc., Teamm Pharmaceuticals, Inc., The Analytica Group, Inc., BioVest Inc., Regent Court
Technologies, Hopkins Capital Group, LLC, Hopkins Capital Group II, LLC, Moab Investments, LP, Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., any affiliates of any of the foregoing, any and all obligations of any of the foregoing
persons and entities (or their affiliates) owing to McKesson or to any other person or entity, or any other matter whatsoever, save and except only McKesson’s obligations to be performed after the date hereof under Agreement. 
 It is the intention of each of the undersigned persons and entities that the foregoing release shall be effective as a bar to all actions, fees, damages,
losses, claims, liabilities, demands or debts whatsoever, of any kind or nature, known or unknown, suspected or unsuspected. Each of the undersigned persons or entities expressly waives any and all rights and benefits conferred upon him or it by
virtue of California Code of Civil Procedure section 1542 (or any similar law with application to any of the undersigned parties) which provides as follows: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT
WITH THE DEBTOR. 
 Each of the undersigned persons or entities expressly acknowledges that McKesson has separately bargained for the
foregoing waiver of the provisions of California Code of Civil Procedure section 1542 and each has been advised by his or its own counsel of the full legal consequences of this release and waiver. 
  

 15 

 This Consent may be executed in any number of counterparts and by different parties hereto in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. 
  

			
	
	  

	FRANCIS E. O’DONNELL, JR., M.D.
	
	  

	DENNIS L. RYLL, M.D.
	
	  

	ALAN PEARCE
	
	REGENT COURT TECHNOLOGIES
		
	By:	 	  

		 	Francis E. O’Donnell, Jr., M.D.
		 	Managing Member
	
	HOPKINS CAPITAL GROUP II, LLC
		
	By:	 	  

		 	Francis E. O’Donnell, Jr., M.D.
		 	Managing Member
	
	HOPKINS CAPITAL GROUP, LLC
		
	By:	 	  

	Title:	 	Managing Member

  

							
	MOAB INVESTMENTS, LP
		
	By:	 	  

			
		 	By:	 	  

				
		 		 	Title:	 	  

		 		 		 	Its General Partner

  

 16 

 EXHIBIT C 
 Example of Calculation of Issuance of Additional Stock 
 If the Closing Date is assumed to be
August 2, 2007, then if the per share stock price for all Additional Stock is $2.67 per share and no Saleability Steps are completed by the first anniversary of the Closing Date (i.e., by August 2, 2008), the schedule of Additional
Stock to be issued and delivered would be as follows: 
 Registration Date: 120 days after the Closing Date or November 30, 2007. 
 Dates when Additional Stock Delivered and number of shares: 
  

					
			
	 December 1, 2007
	 	9,364 shares	 	
			
	 December 31, 2007
 (day after the date that is 30 days
 after Registration Deadline)
	 	18,727 shares	 	
			
	 January 30, 2008
 (date that is 61 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 February 29, 2008
 (date that is 91 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 March 30, 2008
 (date that is 121 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 April 29, 2008
 (date that is 151 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 May 29, 2008
 (date that is 181 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 June 28, 2008
 (date that is 211 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 July 28, 2008
 (date that is 241 days
 after Registration Deadline)
	 	37,454 shares	 	
			
	 First Anniversary of the Closing Date
	 	37,454 shares	 	
			
	TOTAL ADDITIONAL STOCK:	 	327,723 shares	 	

  

 17Exhibit 4.6

 Exhibit 4.6 
 CELSION CORPORATION 
 2007 STOCK INCENTIVE PLAN 
 Effective: June 13, 2007 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	1.	  	Establishment, Purpose and Types of Awards	  	3
	2.	  	Definitions	  	3
	3.	  	Administration	  	5
		  	(a) Procedure	  	5
		  	(b) Secondary Committees and Sub-Plans	  	5
		  	(c) Powers of the Committee	  	6
		  	(d) Limited Liability	  	6
		  	(e) Indemnification	  	6
		  	(f) Effect of Committee’s Decision	  	6
		  	(g) Apprising the Board	  	7
	4.	  	Stock Available Under the Plan; Maximum Awards	  	7
		  	(a) Stock Available Under the Plan	  	7
		  	(b) Maximum Awards to Covered Employees	  	7
	5.	  	Participation	  	7
	6.	  	Stock Options	  	7
		  	(a) Grant of Option	  	8
		  	(b) Exercise Price	  	8
		  	(c) Payment	  	8
		  	(d) Term of Options	  	8
		  	(e) Restrictions on Incentive Stock Options	  	8
		  	(f) Other Terms and Conditions	  	9
	7.	  	Restricted Stock and Restricted Stock Units	  	9
		  	(a) In General	  	9
		  	(b) Vesting Conditions and Other Restrictions	  	9
		  	(c) Stock Issuance and Stockholder Rights	  	9
	8.	  	Stock Appreciation Rights	  	9
		  	(a) Award of Stock Appreciation Rights	  	9
		  	(b) Restrictions of Tandem SARs	  	10
		  	(c) Amount of Payment upon Exercise of SARs	  	10
		  	(d) Form of Payment upon Exercise of SARs	  	10
	9.	  	Phantom Stock	  	10
	10.	  	Performance Awards	  	10
		  	(a) In General	  	10
		  	(b) Covered Employee Targets	  	10
	11.	  	Withholding and Reporting of Taxes	  	11
	12.	  	Transferability	  	11
	13.	  	Adjustments; Business Combinations	  	11
		  	(a) Adjustments	  	11
		  	(b) Change in Control	  	11
		  	(c) Dissolution and Liquidation	  	11
		  	(d) Other Adjustments	  	12
	14.	  	Termination and Amendment	  	12
		  	(a) Amendment or Termination by the Board	  	12
		  	(b) Amendments by the Committee	  	12
		  	(c) Approval of Grantees	  	12
	15.	  	Non-Guarantee of Employment	  	12
	16.	  	Termination of Employment	  	12
	17.	  	Written Agreement	  	13
	18.	  	Non-Uniform Determinations	  	13
	19.	  	Limitation on Benefits	  	13
	20.	  	Listing and Registration	  	13

					
	21.	  	Compliance with Securities Law	  	13
	22.	  	No Trust or Fund Created	  	13
	23.	  	No Limit on Other Compensation Arrangements	  	14
	24.	  	No Restriction of Corporate Action	  	14
	25.	  	Governing Law	  	14
	26.	  	Plan Subject to Charter and Bylaws	  	14
	27.	  	Effective Date; Termination Date	  	14

 CELSION CORPORATION 
 2007 STOCK INCENTIVE PLAN 
  

	1.	Establishment, Purpose and Types of Awards 

 Celsion
Corporation, a Delaware corporation (the Company), hereby establishes the Celsion Corporation 2007 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to promote the long-term growth and profitability of the “Company”
by (i) providing incentives to improve stockholder value and to contribute to the growth and financial success of the Company, and (ii) enabling the Company to attract, retain and reward the best available persons for positions of
substantial responsibility. 
 The Plan permits the granting of Awards in the form of Incentive Stock Options, Nonqualified Stock Options,
Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Phantom Stock, and Performance Awards, in each case as such term is defined below, and any combination of the foregoing. 
  

	2.	Definitions 

 Under this Plan, except where the
context otherwise indicates, the following definitions apply: 
 (a) “Affiliate” shall mean any entity other than a
Subsidiary, if the Company and/or one or more Subsidiaries own directly or indirectly not less than fifty percent (50%) of such entity. 
 (b) “Awards” shall mean Incentive Stock Options, Nonqualified Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Phantom Stock, and Performance Awards, and any combination of the foregoing.

 (c) “Board” shall mean the Board of Directors of the Company. 
 (d) “Change in Control” shall mean: 
 (i) The consummation of an amalgamation, merger or consolidation of the Company with or into another entity or any other corporate reorganization of the Company, if more than fifty percent (50%) of the combined
voting power of the continuing or surviving entity’s securities outstanding immediately after such amalgamation, merger, consolidation or other reorganization (or, if applicable, more than fifty percent (50%) of the combined voting power
of the ultimate parent company that directly or indirectly has beneficial ownership of the securities of such continuing or surviving entity) is not owned directly or indirectly by persons who were holders of the Company’s then-outstanding
voting securities immediately prior to such amalgamation, merger, consolidation or other reorganization; 
 (ii) The sale,
transfer or other disposition of all or substantially all of the Company’s assets to an entity that is not a Parent, a Subsidiary or an Affiliate of the Company; 
 (iii) Any transaction as a result of which any person becomes the “beneficial owner” (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of securities of the Company representing at least fifty percent (50%) of the total voting power represented by the Company’s then-outstanding voting securities. For purposes of this subsection, the
term “person” shall have the same meaning as when used in sections 13(d) and 14(d) of the Exchange Act but shall exclude: (A) any Parent, Subsidiary or Affiliate of the Company, (B) any employee benefit plan (or related trust)
sponsored or maintained by the Company, a Parent, or any Subsidiary or Affiliate, and (C) any underwriter temporarily holding securities pursuant to an offering of such securities; or 
 (iv) A change in the composition of the Board over a period of twenty four (24) consecutive months or less as a result of which
individuals who, at the beginning of such period, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual subsequently becoming a director
whose election, or nomination for election by the Company’s Stockholders, was approved by a vote of at least a majority of the directors then comprising the Board (either by a specific vote or by approval of the proxy statement of the Company
in which such person is named as a nominee for director, without written objection to such nomination) shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose
initial assumption of office occurs as a result of either an actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board. 

 (e) “Code” shall mean the Internal Revenue Code of 1986, as amended, and any regulations
issued thereunder. 
 (f) “Committee” shall mean the Board or a committee of the Board appointed pursuant to Section 3
of the Plan to administer the Plan. 
 (g) “Committee Delegate” shall mean the Chief Executive Officer or other
senior officer of the Company to whom duties and powers of the Board or Committee hereunder have been delegated pursuant to Section 3(c).  
 (h) “Covered Employee” shall mean an employee of the Company or any Parent, Subsidiary or Affiliate who is subject to Code Section 162(m). 
 (i) “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended and any rules or regulations promulgated thereunder.

 (j) “Fair Market Value” of the Stock for any purpose on a particular date shall mean: 
 (i) if the Stock is traded on a public securities exchange or a national automated quotation system, the closing price for Stock on the
relevant date, or (if there were no sales on such date) the closing price on the nearest day before the relevant date, as reported in The Wall Street Journal or a similar publication selected by the Committee; or 
 (ii) if the Stock is not traded on a public securities exchange or a national quotation system on such date, the price determined in a
manner such as the Committee shall in good faith determine to be appropriate. 
 (k) “Grant Agreement” shall mean a written
agreement between the Company and a grantee memorializing the terms and conditions of an Award granted pursuant to the Plan. 
 (l)
“Grant Date” shall mean the date on which the Committee formally acts to grant an Award to a grantee or such other date as the Committee shall so designate at the time of taking such formal action. 
 (m) “Incentive Stock Options” shall mean Stock options that meet the requirements of Code Section 422. 
 (n) “Nonqualified Stock Options” shall mean Stock options that do not meet the requirements of Code Section 422. 
 (o) “Parent” shall mean a company, whether now or hereafter existing, within the meaning of the definition of “parent company”
provided in Section 424(e) of the Code, or any successor thereto of similar import. 
 (p) “Participant” shall mean a
director, officer, employee or consultant of the Company, or any Parent, Subsidiary or Affiliate, who is granted an Award under the Plan. 
 (q) “Performance Award” shall mean an Award under Section 9 hereof. 
 (r) “Performance
Measure” shall mean one or more of the following criteria selected by the Committee to measure performance of the Company or any Parent, Subsidiary or Affiliate or other business division of same for a Performance Period, whether in
absolute or relative terms: basic or diluted earnings per share of Stock; earnings per share of Stock growth; revenue; operating income; net income (either before or after taxes); earnings and/or net income before interest and taxes; earnings and/or
net income before interest, taxes, depreciation and amortization; return on capital; return on equity; return on assets; net cash provided by operations; free cash flow; Stock price; economic profit; economic value; total stockholder return; gross
margins and costs. Each such measure shall be determined in accordance with generally accepted accounting principles as consistently applied and, if so determined by the Committee and, in the case of a Performance Award to a Covered Employee, to the
extent permitted under Code Section 162(m), adjusted to omit the effects of extraordinary items, gain or loss on the disposal of a business segment, unusual or infrequently occurring events and transactions and cumulative effects of changes in
accounting principles. 
 (s) “Performance Period” means a period of not less than one year over which the achievement of
targets for Performance Measures is determined. 

 (t) “Phantom Stock” shall mean Awards under Section 9. 
 (u) “Restricted Stock” and “Restricted Stock Units” shall mean Awards under Section 7. 
 (v) “Rule 16b-3” shall mean Rule 16b-3 as in effect under the Exchange Act on the effective date of the Plan, or any successor provision
prescribing conditions necessary to exempt the issuance of securities under the Plan (and further transactions in such securities) from Section 16(b) of the Exchange Act. 
 (w) “Securities Act” shall mean the U.S. Securities Act of 1933, as amended and any rules or regulations promulgated thereunder.

 (x) “Stock” shall mean common stock of the Company, par value $0.01 per share. 
 (y) “Stock Appreciation Rights” shall mean Awards under Section 8(a) to (d). 
 (z) “Subsidiary” and “Subsidiaries” shall mean only a company or companies, whether now or hereafter existing, within the
meaning of the definition of “subsidiary company” provided in Section 424(f) of the Code, or any successor thereto of similar import. 
 (aa) “2001 Plan” shall mean the 2001 Celsion Corporation Stock Option Plan. 
 (bb)
“2004 Plan” shall mean the Celsion Corporation 2004 Stock Incentive Plan. 
  

	3.	Administration 

 (a) Procedure. The Plan
shall be administered by the Board. In the alternative, the Board may delegate authority to a Committee to administer the Plan on behalf of the Board, subject to such terms and conditions as the Board may prescribe. Such Committee shall consist of
not less than two (2) members of the Board each of whom is a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act, or any successor rule of similar import, and an “outside director” within the
meaning of Section 162(m) of the Code and the regulations promulgated thereunder. 
 Once appointed, the Committee shall continue to
serve until otherwise directed by the Board. From time to time, the Board may increase the size of the Committee and appoint additional members thereof, remove members (with or without cause) and appoint new members in substitution therefor, fill
vacancies, however caused, and remove all members of the Committee and, thereafter, directly administer the Plan. In the event that the Board is the administrator of the Plan in lieu of a Committee, the term “Committee” as used herein
shall be deemed to mean the Board. 
 Members of the Board or Committee who are either eligible for Awards or have been granted Awards may
vote on any matters affecting the administration of the Plan or the grant of Awards pursuant to the Plan, except that no such member shall act upon the granting of an Award to himself or herself, but any such member may be counted in determining the
existence of a quorum at any meeting of the Board or the Committee during which action is taken with respect to the granting of an Award to him or her. 
 The Committee shall meet at such times and places and upon such notice as it may determine. A majority of the Committee shall constitute a quorum. Any acts by the Committee may be taken at any meeting at which a
quorum is present and shall be by majority vote of those members entitled to vote. Additionally, any acts reduced to writing or approved in writing by all of the members of the Committee shall be valid acts of the Committee. 
 (b) Secondary Committees and Sub-Plans. The Board may, in its sole discretion, divide the duties and powers of the Committee by establishing one
or more secondary Committees to which certain duties and powers of the Board hereunder are delegated (each of which shall be regarded as a “Committee” under the Plan with respect to such duties and powers), or delegate all of its duties
and powers hereunder to a single Committee. Additionally, if permitted by applicable law, the Board or Committee may delegate any or all of its duties and powers hereunder to the Chief Executive Officer and/or to other senior officers of the Company
subject to such conditions and limitations as the Board or Committee shall prescribe. However, only the Committee described under Subsection 3(a) may designate and grant Awards to Participants who are subject to Section 16 of the Exchange Act
or Section 162(m) of the Code. The Committee shall also have the power to establish sub-plans (which may be included as appendices to the Plan or the respective Grant Agreements), which may constitute separate schemes, for the purpose of
establishing schemes which meet any special tax or regulatory requirements of jurisdictions other than the United States and its subdivisions. Any such interpretations, rules, administration and sub-plans shall be consistent with the basic purposes
of the Plan. 

 (c) Powers of the Committee. The Committee shall have all the powers vested in it by the terms of
the Plan, such powers to include authority, in its sole and absolute discretion, to grant Awards under the Plan, prescribe Grant Agreements evidencing such Awards and establish programs for granting Awards. The Committee shall have full power and
authority to take all other actions necessary to carry out the purpose and intent of the Plan, including, but not limited to, the authority to: 
 (i) determine the Participants to whom, and the time or times at which, Awards shall be granted, 
 (ii) determine the types of Awards to be granted, 
 (iii) determine the number of shares of Stock and/or amount of
cash to be covered by or used for reference purposes for each Award, 
 (iv) impose such terms, limitations, vesting
schedules, restrictions and conditions upon any such Award as the Committee shall deem appropriate, including without limitation establishing, in its discretion, Performance Measures that must be satisfied before an Award vests and/or becomes
payable, the term during which an Award is exercisable, the purchase price, if any, under an Award and the period, if any, following a grantee’s termination of employment or service with the Company or any Parent, Subsidiary or Affiliate during
which the Award shall remain exercisable, 
 (v) modify, extend or renew outstanding Awards, accept the surrender of
outstanding Awards and substitute new Awards, provided that no such action shall be taken with respect to any outstanding Award that would materially, adversely affect the grantee without the grantee’s consent, or constitute a repricing of
stock options without the consent of the holders of the Company’s voting securities under (vi) below, 
 (vi) only
with the approval of the holders of the voting securities of the Company to the extent that such approval is required by applicable law, the regulation or the rules of an national securities exchange or automated quotation system to which the
Company is subject, reprice Incentive Stock Options and Nonqualified Stock Options either by amendment to lower the exercise price or by accepting such stock options for cancellation and issuing replacement stock options with a lower exercise price
or through any other mechanism, 
 (vii) accelerate the time in which an Award may be exercised or in which an Award becomes
payable and waive or accelerate the lapse, in whole or in part, of any restriction or condition with respect to an Award, 
 (viii) establish objectives and conditions, including targets for Performance Measures, if any, for earning Awards and determining whether Awards will be paid after the end of a Performance Period, and 
 (ix) permit the deferral of, or require a Participant to defer such Participant’s receipt of, the delivery of Stock and/or cash under
an Award that would otherwise be due to such Participant and establish rules and procedures for such payment deferrals, provided the requirements of Code Section 409A are met with respect to any such deferral. 
 The Committee shall have full power and authority to administer and interpret the Plan and to adopt such rules, regulations, agreements, guidelines and instruments for
the administration of the Plan as the Committee deems necessary, desirable or appropriate in accordance with the Bylaws of the Company. 
 (d) Limited Liability. To the maximum extent permitted by law, no member of the Board or Committee or a Committee Delegate shall be liable for any action taken or decision made in good faith relating to the Plan or any Award
thereunder. 
 (e) Indemnification. The members of the Board and Committee and any Committee Delegate shall be indemnified by the
Company in respect of all their activities under the Plan in accordance with the procedures and terms and conditions set forth in the Certificate of Incorporation Bylaws of the Company as in effect from time to time. The foregoing right of
indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Certificate of Incorporation, as a matter of law, or otherwise. 
 (f) Effect of Committee’s Decision. All actions taken and decisions and determinations made by the Committee or a Committee Delegate on all
matters relating to the Plan pursuant to the powers vested in it hereunder shall be in the Committee’s or 

 
Committee Delegate’s sole and absolute discretion and shall be conclusive and binding on all parties concerned, including the Company, its stockholders,
any Participants in the Plan and any other employee of the Company, and their respective successors in interest. 
 (g) Apprising the
Board. The Committee will inform the Board regarding its activities under the Plan not less frequently than at each scheduled Board meeting and at such other times as the Board may request. 
  

	4.	Stock Available Under the Plan; Maximum Awards 

 (a)
Stock Available Under the Plan.  
 (i) Subject to adjustments as provided in Section 13 of the Plan, the Stock
that may be delivered or purchased or used for reference purposes (with respect to Stock Appreciation Rights, or Phantom Stock) with respect to Awards granted under the Plan, including with respect to Incentive Stock Options, shall not exceed an
aggregate of one million (1,000,000) shares of Stock, plus the number of shares of Stock available from the 2001 Plan and 2004 Plan as provided in Subsection 4(a)(ii) below. Stock available under the Plan may be, in any combination, authorized
but unissued Stock, treasury Stock and Stock that is repurchased, in the market, and canceled by the Company. The Company shall reserve said number of shares of Stock for Awards under the Plan, subject to adjustments as provided in Section 13
of the Plan. If any Award, or portion of an Award, issued under the Plan, expires or terminates unexercised, becomes unexercisable or is forfeited or otherwise terminated, surrendered or canceled as to any shares of Stock without the delivery by the
Company (or, in the case of Restricted Shares, without vesting) of Stock or other consideration, the Stock subject to such Award shall thereafter be available for further Awards under the Plan. 
 (ii) There shall be available for issuance under the Plan the sum of (A) the number of shares of Stock remaining available for
issuance under the 2004 Plan at the effective date of this Plan, plus (B) shares of Stock subject to any stock options issued under the 2001 Plan or 2004 Plan to the extent such stock options subsequently expire or terminate unexercised, become
unexercisable or are forfeited or otherwise terminated, surrendered or canceled, without delivery of shares of Stock or other consideration to the holder. 
 (b) Maximum Awards to Covered Employees. The maximum number of shares of Stock subject to Awards that may be granted during any one calendar year to any one Covered Employee shall be limited to two million
(200,000). To the extent required by Section 162(m) of the Code and so long as Section 162(m) of the Code is applicable to persons eligible to participate in the Plan, shares of Stock subject to the foregoing maximum with respect to which
the related Award is terminated, surrendered or canceled shall nonetheless continue to be taken into account with respect to such maximum for the calendar year in which granted. 
  

	5.	Participation 

 Participation in the Plan shall be
open to all directors, officers, employees and consultants of the Company, or of any Parent, Subsidiary or Affiliate of the Company, as may be selected by the Committee from time to time. Notwithstanding the foregoing, participation in the Plan with
respect to Awards of Incentive Stock Options shall be limited to employees of the Company or of any Parent or Subsidiary of the Company. 
 Awards may be granted to such Participants and for or with respect to such number of shares of Stock as the Committee shall determine, subject to the limitations in Section 4 of the Plan. A grant of any type of Award made in any one
year to a Participant shall neither guarantee nor preclude a further grant of that or any other type of Award to such person in that year or subsequent years. 
  

	6.	Stock Options 

 Subject to the other applicable
provisions of the Plan, the Committee may from time to time grant to Participants Awards of Nonqualified Stock Options and/or Incentive Stock Options. The stock option Awards granted shall be subject to the following terms and conditions.

 (a) Grant of Option. The grant of a stock option shall be evidenced by a Grant Agreement, executed
by the Company and the grantee, stating the number of shares of Stock subject to the stock option evidenced thereby, the exercise price and the terms and conditions of such stock option, in such form as the Committee may from time to time determine.

 (b) Exercise Price. The price per share payable upon the exercise of each stock option shall be determined by the Committee, but
shall not be less than the Fair Market Value of the shares on the Grant Date, unless the stock option complies with Section 409A of the Code. 
 (c) Payment. Stock options may be exercised in whole or in part by payment of the exercise price of the Stock to be acquired in accordance with the provisions of the Grant Agreement, and/or such rules and regulations as the Committee
may have prescribed, and/or such determinations, orders, or decisions as the Committee may have made. Payment may be made in cash (or cash equivalents acceptable to the Committee) or, if provided in the Grant Agreement and permitted by applicable
law, in shares of Stock which have been held by grantee for at least six (6) months, or a combination of cash and such Stock, or by such other means as the Committee may prescribe. The Fair Market Value of Stock delivered on exercise of stock
options shall be determined as of the date of exercise. 
 If the Stock is registered under Section 12(b) or 12(g) of the Exchange Act,
the Committee, subject to such limitations as it may determine, may authorize payment of the exercise price, in whole or in part, by delivery of a properly executed exercise notice, together with irrevocable instructions, to: (i) a brokerage
firm to deliver promptly to the Company the aggregate amount of sale or loan proceeds to pay the exercise price and any withholding tax obligations that may arise in connection with the exercise, and (ii) the Company to deliver the certificates
for such purchased Stock directly to such brokerage firm. 
 (d) Term of Options. The term during which each stock option may be
exercised shall be determined by the Committee; provided, however, that in no event shall a stock option be exercisable more than ten years from the date it is granted. Prior to the exercise of the stock option and delivery of the Stock certificates
represented thereby, the grantee shall have none of the rights of a stockholder with respect to any Stock represented by an outstanding stock option. 
 (e) Restrictions on Incentive Stock Options. Incentive Stock Option Awards granted under the Plan shall comply in all respects with Code Section 422 and, as such, shall meet the following additional
requirements: 
 (i) Grant Date. An Incentive Stock Option must be granted within ten (10) years of the earlier of
the Plan’s adoption by the Board of Directors or approval by the Company’s stockholders. 
 (ii) Exercise Price
and Term. The exercise price of an Incentive Stock Option shall not be less than one hundred percent (100%) of the Fair Market Value of the Stock on the date the stock option is granted and the term of the stock option shall not exceed ten
(10) years. Also, the exercise price of any Incentive Stock Option granted to a grantee who owns (within the meaning of Section 422(b)(6) of the Code, after the application of the attribution rules in Section 424(d) of the Code) more
than ten percent (10%) of the total combined voting power of all classes of shares of Stock of the Company or any Parent or Subsidiary of the Company shall be not less than one hundred ten percent (110%) of the Fair Market Value of the
Stock on the grant date and the term of such stock option shall not exceed five (5) years. 
 (iii) Maximum Grant.
The aggregate Fair Market Value (determined as of the Grant Date) of Stock of the Company with respect to which all Incentive Stock Options first become exercisable by any grantee in any calendar year under this or any other plan of the Company and
its Parent and Subsidiaries may not exceed One Hundred Thousand Dollars ($100,000) or such other amount as may be permitted from time to time under Section 422 of the Code. To the extent that such aggregate Fair Market Value shall exceed One
Hundred Thousand Dollars ($100,000), or other applicable amount, such stock options to the extent of the Stock in excess of such limit shall be treated as Nonqualified Stock Options. In such case, the Company may designate the shares of Stock that
are to be treated as Stock acquired pursuant to the exercise of an Incentive Stock Option. 
 (iv) Grantee. Incentive
Stock Options shall only be issued to employees of the Company or of a Parent, Subsidiary or Affiliate of the Company. 
 (v)
Designation. No stock option shall be an Incentive Stock Option unless so designated by the Committee at the time of grant or in the Grant Agreement evidencing such stock option. 

 (vi) Stockholder Approval. No stock option issued under the Plan shall be an
Incentive Stock Option unless the Plan is approved by the stockholders of the Company within twelve (12) months of its adoption by the Board in accordance with the Bylaws of the Company and governing law relating to such matters. 
 (f) Other Terms and Conditions. Stock options may contain such other provisions, not inconsistent with the provisions of the Plan, as the
Committee shall determine appropriate from time to time. 
  

	7.	Restricted Stock and Restricted Stock Units 

 (a)
In General. Subject to the other applicable provisions of the Plan and applicable law, the Committee may at any time and from time to time grant Restricted Stock or Restricted Stock Units to Participants, in such amounts and subject to such
vesting conditions, other restrictions and conditions for removal of restrictions as it determines. Unless determined otherwise by the Committee, Participants receiving Restricted Stock or Restricted Stock Units are not required to pay the Company
cash consideration therefor (except as may be required for applicable tax withholding). 
 (b) Vesting Conditions and Other Restrictions.
Each Award for Restricted Stock and Restricted Stock Units shall be evidenced by a Grant Agreement that specifies the applicable vesting conditions and other restrictions, if any, on such Award, the duration of such restrictions, and the time or
times at which such restrictions shall lapse with respect to all or a specified number of the shares of Stock that are part of the Award. Notwithstanding the foregoing, the Committee may reduce or shorten the duration of any vesting or other
restriction applicable to any Restricted Stock or Restricted Stock Units awarded to any grantee under the Plan. 
 (c) Stock Issuance and
Stockholder Rights. 
 (i) Restricted Stock. Stock certificates with respect to Stock granted pursuant to a Restricted
Stock Award shall be issued, and/or Stock shall be registered, at the time of grant of the Restricted Stock Award, subject to forfeiture if the Restricted Stock does not vest or other restrictions do not lapse. Any Stock certificates shall bear an
appropriate legend with respect to the restrictions applicable to such Restricted Stock Award and the grantee may be required to deposit the certificates with the Company during the period of any restriction thereon and to execute a blank stock
power or other instrument of transfer therefor. Except as otherwise provided by the Committee, during the period of restriction following issuance of Restricted Stock certificates, the grantee shall have all of the rights of a holder of Stock,
including but not limited to the rights to receive dividends (or amounts equivalent to dividends) and to vote with respect to the Restricted Stock. The Committee, in its discretion, may provide that any dividends or distributions paid with respect
to Stock subject to the unvested portion of a Restricted Stock Award will be subject to the same restrictions as the Restricted Stock to which such dividends or distributions relate. 
 (ii) Restricted Stock Units. Stock certificates for the shares of Stock subject to a Restricted Stock Unit shall be issued, and/or Stock
shall be registered, upon vesting and lapse of any other restrictions with respect to the issuance of Stock under such Award. The grantee will not be entitled to vote such Stock or to any of the other rights of stockholders during the period prior
to issuance of the certificates for such Stock and/or the registration of the Stock. An Award of Restricted Stock Units may provide the Participant with the right to receive amounts equivalent to dividends and distributions paid with respect to
Stock subject to the Award while the Award is outstanding, which payments may, in the Committee’s discretion, either be made currently or credited to an account for the Participant, and may be settled in cash or Stock, all as determined by the
Committee. Unless otherwise determined by the Committee with respect to a particular Award, each outstanding Restricted Stock Unit shall accrue such dividend equivalents, deferred as equivalent amounts of additional Restricted Stock Units, which
amounts will be paid only when and if the Restricted Stock Unit (on which such dividend equivalents were accrued) vests and becomes payable. To the extent that a Restricted Stock Unit does not vest or is otherwise forfeited, any accrued and unpaid
dividend equivalents shall be forfeited. 
  

	8.	Stock Appreciation Rights 

 (a) Award of Stock
Appreciation Rights. Subject to the other applicable provisions of the Plan, the Committee may at any time and from time to time grant Stock Appreciation Rights (“SARs”) to Participants, either on a free-standing basis (without regard
to or in addition to the grant of a stock option) or on a tandem basis (related to the grant of an underlying stock option), as it determines. SARs granted in tandem with or in addition to a stock option may be granted either at the same time as the
stock option or at a later time; provided, however, that a tandem SAR shall not be granted with respect to any outstanding Incentive Stock Option Award without the consent of the grantee. SARs shall be evidenced by Grant Agreements, executed by the
Company and the grantee, stating the number of shares of Stock subject to the SAR evidenced thereby and the terms and conditions of such SAR, in such form as 

 
the Committee may from time to time determine. The term during which each SAR may be exercised shall be determined by the Committee. In no event shall a SAR
be exercisable more than ten years from the date it is granted. The grantee shall have none of the rights of a stockholder with respect to any Stock represented by a SAR. 
 (b) Restrictions of Tandem SARs. No Incentive Stock Option may be surrendered in connection with the exercise of a tandem SAR unless the Fair
Market Value of the Stock subject to the Incentive Stock Option is greater than the exercise price for such Incentive Stock Option. SARs granted in tandem with stock options shall be exercisable only to the same extent and subject to the same
conditions as the stock options related thereto are exercisable. The Committee may, in its discretion, prescribe additional conditions to the exercise of any such tandem SAR. 
 (c) Amount of Payment upon Exercise of SARs. A SAR shall entitle the grantee to receive, subject to the provisions of the Plan and the Grant
Agreement, a payment having an aggregate value equal to the product of (i) the excess of (A) the Fair Market Value on the exercise date of one share of Stock over (B) the base price per share of Stock specified in the Grant Agreement,
times (ii) the number of shares of Stock specified by the SAR, or portion thereof, that is exercised. In the case of exercise of a tandem SAR, such payment shall be made in exchange for the surrender of the unexercised related stock option (or
any portion or portions thereof which the grantee from time to time determines to surrender for this purpose). The base price per share under a SAR shall not be less than the Fair Market Value of a share of Stock on the Grant Date, unless the SAR
complies with Section 409A of the Code. 
 (d) Form of Payment upon Exercise of SARs. Payment by the Company of the amount
receivable upon any exercise of a SAR may be made by the delivery of Stock or cash, or any combination of Stock and cash, as determined in the sole discretion of the Committee from time to time. If upon settlement of the exercise of a SAR a grantee
is to receive a portion of such payment in Stock, the number of shares of Stock shall be determined by dividing such portion by the Fair Market Value of a share of Stock on the exercise date. No fractional shares shall be used for such payment and
the Committee shall determine whether cash shall be given in lieu of such fractional shares or whether such fractional shares shall be eliminated. 
  

	9.	Phantom Stock 

 The grant of Phantom Stock shall be
evidenced by a Grant Agreement, executed by the Company and the grantee, that incorporates the terms of the Plan and states the number of shares of Phantom Stock evidenced thereby and the terms and conditions of such Phantom Stock in such form as
the Committee may from time to time determine. Phantom Stock granted to a Participant shall be credited to a bookkeeping reserve account solely for accounting purposes and shall not require a segregation of any of the Company’s assets. Each
share of Phantom Stock shall represent the value of one share of Stock. Phantom Stock shall become payable in whole or in part in such form, at such time or times and pursuant to such conditions in accordance with the provisions of the Grant
Agreement, and/or such rules and regulations as the Committee may prescribe, and/or such determinations, orders or decisions as the Committee may make. Except as otherwise provided in the applicable Grant Agreement, the grantee shall have none of
the rights of a stockholder with respect to any shares represented by Phantom Stock as a result of the grant of Phantom Stock to the grantee. Phantom Stock may contain such other provisions, not inconsistent with the provisions of the Plan, as the
Committee shall determine desirable or appropriate from time to time. 
  

	10.	Performance Awards 

 (a) In General. The
Committee, in its discretion, may establish targets for Performance Measures for selected Participants and authorize the granting, vesting, payment and/or delivery of Performance Awards in the form of Incentive Stock Options, Nonqualified Stock
Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, and/or Phantom Stock to such Participants upon achievement of such targets for Performance Measures during a Performance Period. The Committee, in its discretion, shall
determine the Participants eligible for Performance Awards, the targets for Performance Measures to be achieved during each Performance Period, and the type, amount, and terms and conditions of any Performance Awards. Performance Awards may be
granted either alone or in addition to other Awards made under the Plan. 
 (b) Covered Employee Targets. After the Company is subject
to Code Section 162(m), in connection with any Performance Awards granted to a Covered Employee, the Committee shall (i) establish in the applicable Grant Agreement the specific targets relative to the Performance Measures which must be
attained before the respective Performance Award is granted, vests, or is otherwise paid or delivered, (ii) provide in the applicable Grant Agreement the method for computing the portion of the Performance Award which shall be granted, vested,
paid and/or delivered if the target or targets are attained in full or part, and (iii) at the end of the relevant Performance Period and prior to any such grant, vesting, payment or delivery certify the extent to which the applicable target or
targets were achieved and whether any other material terms were in fact satisfied. The specific targets and the method for computing the portion of such Performance Award which shall be granted, vested, paid or delivered to any Covered Employee
shall be 

 
established by the Committee prior to the earlier to occur of (A) ninety (90) days after the commencement of the Performance Period to which the
Performance Measure applies and (B) the elapse of twenty-five percent (25%) of the Performance Period and in any event while the outcome is substantially uncertain. In interpreting Plan provisions applicable to Performance Measures and
Performance Awards with respect to Covered Employees, it is the intent of the Plan to conform with the standards of Section 162(m) of the Code and Treasury Regulations Section 1.162-27(e)(2)(i), and the Committee in interpreting the Plan
shall be guided by such provisions. 
  

	11.	Withholding and Reporting of Taxes 

 The Company may
require, as a condition to the grant of any Award under the Plan, vesting or exercise pursuant to such Award or to the delivery of certificates for shares of Stock issued or payments of cash to a grantee pursuant to the Plan or a Grant Agreement,
that the grantee pay to the Company, in cash or, if approved by the Company, in Stock, including Stock acquired upon grant of the Award or exercise of the Award, valued at Fair Market Value on the date as of which the withholding tax liability is
determined, any federal, state or local taxes of any kind or any applicable taxes or other required withholding of any other jurisdiction required by law to be withheld with respect to any taxable event under the Plan. The Company, to the extent
permitted or required by law, shall have the right to deduct from any payment of any kind (including salary or bonus) otherwise due to a grantee any federal, state or local taxes of any kind or any applicable taxes or other required withholding of
any other jurisdiction required by law to be withheld with respect to the grant, vesting, exercise or payment of or under any Award under the Plan or a Grant Agreement, or to retain or sell a sufficient number of the shares of Stock to be issued to
such grantee to cover any such taxes. The Company or any Parent, Subsidiary or Affiliate shall comply with any applicable tax reporting requirements of any jurisdiction imposed on it by law with respect to the granting, vesting, exercise and/or
payment of Awards. 
  

	12.	Transferability 

 No Award granted under the Plan
shall be transferable by a grantee otherwise than by will or the laws of descent and distribution. Unless otherwise determined by the Committee in accordance with the provisions of the immediately preceding sentence, an Award may be exercised during
the lifetime of the grantee only by the grantee or, during the period the grantee is under a legal disability, by the grantee’s guardian or legal representative. Notwithstanding the foregoing, an Award other than an Incentive Stock Option may,
in the Committee’s sole discretion, be transferable by gift or domestic relations order to (i) the grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law,
father-in-law, daughter-in-law, son-in-law, brother-in-law or sister-in-law, including adoptive relationships (such persons, “Family Members”), (ii) a company, partnership, limited liability company or other business entity whose only
stockholders, partners or members, as applicable are the grantee and/or Family Members, or (iii) a trust in which the Grantee and/or Family Members have all of the beneficial interests, and subsequent to any such transfer any Award may be
exercised by any such transferee. 
  

	13.	Adjustments; Business Combinations 

 (a)
Adjustments. In the event of a reclassification, recapitalization, stock split, reverse stock split, stock dividend, combination of shares or other similar event, the maximum number and kind of shares reserved for issuance or with respect to
which Awards may be granted under the Plan as provided in Section 4 shall be adjusted to reflect such event, and the Committee shall make such adjustments as it deems appropriate and equitable in the number, kind and price of shares covered by
outstanding Awards made under the Plan, and in any other matters that relate to Awards and that are affected by the changes in the shares referred to above. 
 (b) Change in Control. In the event of any proposed Change in Control under Section 2(d)(i), (ii) or (iii), the Committee shall take such action as it deems appropriate and equitable to effectuate the
purposes of this Plan and to protect the grantees of Awards, which action may include, without limitation, any one or more of the following, provided such action is in compliance with Code Section 409A if applicable: (i) acceleration or
change of the exercise and/or expiration dates of any Award to require that exercise be made, if at all, prior to the Change in Control; (ii) cancellation of any Award upon payment to the holder in cash of the Fair Market Value of the Stock
subject to such Award as of the date of (and, to the extent applicable, as established for purposes of) the Change in Control, less the aggregate exercise price, if any, of the Award; and (iii) in any case where equity securities of another
entity are proposed to be delivered in exchange for or with respect to Stock of the Company, arrangements to have such other entity replace the Awards granted hereunder with awards with respect to such other securities, with appropriate adjustments
in the number of shares subject to, and the exercise prices under, the Award. 
 (c) Dissolution and Liquidation. In the event the
Company dissolves and liquidates (other than pursuant to a plan of amalgamation, merger or reorganization), then notwithstanding any restrictions on exercise set forth in this Plan or any Grant Agreement, or other agreement evidencing a stock
option, Stock Appreciation Right, Phantom Stock, Restricted Stock or Restricted 

 
Stock Unit Award, provided such action is in compliance with Code Section 409A if applicable: (i) each grantee shall have the right to exercise his
stock option, Stock Appreciation Right, or Phantom Stock or to require delivery of Stock certificates, and/or registration of the Stock, representing any such Restricted Stock or Restricted Stock Unit Award, at any time up to ten (10) days
prior to the effective date of such liquidation and dissolution; and (ii) the Committee may make arrangements with the grantees for the payment of appropriate consideration to them for the cancellation and surrender of any stock option, Stock
Appreciation Right, Phantom Stock, Restricted Stock or Restricted Stock Unit Award that is so canceled or surrendered at any time up to ten (10) days prior to the effective date of such liquidation and dissolution. The Committee may establish a
different period (and different conditions) for such exercise, delivery, cancellation or surrender to avoid subjecting the grantee to liability under Section 16(b) of the Exchange Act. Any stock option, Stock Appreciation Right or Phantom Stock
not so exercised, canceled or surrendered shall terminate on the last day for exercise prior to such effective date; and any Restricted Stock or Restricted Stock Units as to which there has not been such delivery of Stock certificates or that has
not been so canceled or surrendered, shall be forfeited on the last day prior to such effective date. The Committee shall give to each grantee written notice of the commencement of any proceedings for such liquidation and dissolution of the Company
and the grantee’s rights with respect to his outstanding Award. 
 (d) Other Adjustments. The Committee is authorized to make
adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the events described in the preceding paragraphs of this Section 13) affecting the
Company, or the financial statements of the Company or any Parent, Subsidiary or Affiliate, or of changes in applicable laws, regulations or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to
prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan. 
 Except as hereinbefore
expressly provided, issuance by the Company of stock of any class or securities convertible into stock of any class, for cash, property, labor or services, upon direct sale, upon the exercise of rights or warranty to subscribe therefor, or upon
conversion of stock or obligations of the Company convertible into such stock or other securities, and in any case whether or not for fair value, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of
shares of Stock subject to Awards theretofore granted or the purchase price per share of Stock subject to Awards. 
  

	14.	Termination and Amendment 

 (a) Amendment or
Termination by the Board. The Board, without further approval of the stockholders, may amend or terminate the Plan or any portion thereof at any time, except that no amendment shall become effective without prior approval of the stockholders of
the Company to increase the number of shares of Stock subject to the Plan or if stockholder approval is necessary to comply with any tax or regulatory requirement or rule of any exchange or national automated quotation system upon which the Stock is
listed or quoted (including for this purpose stockholder approval that is required for continued compliance with Rule 16b-3 or stockholder approval that is required to enable the Committee to grant Incentive Stock Options pursuant to the Plan).

 (b) Amendments by the Committee. The Committee shall be authorized to make minor or administrative amendments to the Plan as well
as amendments to the Plan that may be dictated by requirements of U.S. federal or state laws applicable to the Company or that may be authorized or made desirable by such laws. The Committee may amend any outstanding Award in any manner as provided
in Sections 3(c) and (d) and to the extent that the Committee would have had the authority to make such Award as so amended. 
 (c)
Approval of Grantees. No amendment to the Plan or any Award may be made that would materially adversely affect any outstanding Award previously made under the Plan without the approval of the grantee. Further, no amendment to the Plan or an
Award shall be made which would cause any Award to fail to either comply with or meet an exception from Code Section 409A. 
  

	15.	Non-Guarantee of Employment 

 Nothing in the Plan or
in any Grant Agreement thereunder shall confer any right on an employee to continue in the employ of the Company or any Parent, Subsidiary or Affiliate or shall interfere in any way with the right of the Company or any Parent, Subsidiary or
Affiliate to terminate an employee at any time. 
  

	16.	Termination of Employment 

 For purposes of
maintaining a grantee’s continuous status as an employee and accrual of rights under any Award, transfer of an employee among the Company and the Company’s Parent, Subsidiaries or Affiliates shall not be considered a termination of
employment. Nor shall it be considered a termination of employment for such purposes if an employee is placed on military or sick 

 
leave or such other leave of absence that is considered as continuing intact the employment relationship; in such a case, the employment relationship shall
be continued until the date when an employee’s right to reemployment shall no longer be guaranteed either by law or contract. 
  

	17.	Written Agreement 

 Each Grant Agreement entered
into between the Company and a grantee with respect to an Award granted under the Plan shall incorporate the terms of this Plan and shall contain such provisions, consistent with the provisions of the Plan, as may be established by the Committee.

  

	18.	Non-Uniform Determinations 

 The Committee’s
determinations under the Plan (including without limitation determinations of the persons to receive Awards, the form, amount and time of such Awards, the terms and provisions of such Awards and the agreements evidencing same) need not be uniform
and may be made by it selectively among persons who receive, or are eligible to receive, Awards under the Plan, whether or not such persons are similarly situated. 
  

	19.	Limitation on Benefits 

 With respect to persons
subject to Section 16 of the Exchange Act, transactions under this Plan are intended to comply with all applicable conditions of Rule 16b-3. To the extent any provision of the Plan or action by the Committee fails to so comply, it shall be
deemed null and void, to the extent permitted by law and deemed advisable by the Committee. 
  

	20.	Listing and Registration 

 If the Company determines
that the listing, registration or qualification upon any securities exchange or upon any listing or quotation system established by the National Association of Securities Dealers, Inc. or under any law of Stock subject to any Award is necessary or
desirable as a condition of, or in connection with, the granting of same or the issue or purchase of Stock thereunder, no such Award may be exercised in whole or in part and no restrictions on such Award shall lapse, unless such listing,
registration or qualification is effected free of any conditions not acceptable to the Company. 
  

	21.	Compliance with Securities Law 

 The Company may
require that a grantee, as a condition to exercise of an Award, and as a condition to the delivery of any Stock certificate, provide to the Company, at the time of each such exercise and each such delivery, a written representation that the Stock
being acquired shall be acquired by the grantee solely for investment and will not be sold or transferred without registration or the availability of an exemption from registration under the Securities Act and applicable state securities laws. The
Company may also require that a grantee submit other written representations that will permit the Company to comply with applicable federal and state securities laws in connection with the issuance of the Stock, including representations as to the
knowledge and experience in financial and business matters of the grantee and the grantee’s ability to bear the economic risk of the grantee’s investment. The Company may require that the grantee obtain a “purchaser
representative” as that term is defined in applicable federal and state securities laws. Any Stock certificates for shares issued pursuant to this Plan may bear a legend restricting transferability of the Stock unless such shares are registered
or an exemption from registration is available under the Securities Act and applicable securities laws of the states of the U.S. The Company may notify its transfer agent to stop any transfer of Stock not made in compliance with these restrictions.
Stock shall not be issued with respect to an Award granted under the Plan unless the exercise of such Award and the issuance and delivery of Stock certificates for such shares pursuant thereto shall comply with all relevant provisions of law,
including, without limitation, the Securities Act, the Exchange Act, the rules and regulations promulgated thereunder and the requirements of any national securities exchange or Nasdaq System upon which the Stock may then be listed or quoted, and
shall be further subject to the approval of counsel for the Company with respect to such compliance to the extent such approval is sought by the Committee. 
  

	22.	No Trust or Fund Created 

 Neither the Plan nor any
Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and a grantee or any other person. To the extent that any grantee or other person acquires a right to receive payments
from the Company pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company. 

	23.	No Limit on Other Compensation Arrangements 

 Nothing contained in the Plan shall prevent the Company or any Parent, Subsidiary or Affiliate from adopting or continuing in effect other compensation arrangements (whether such arrangements be generally applicable or applicable only in
specific cases), including without limitation the granting of stock options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights or Phantom Stock Units otherwise than under the Plan. 
  

	24.	No Restriction of Corporate Action 

 Nothing
contained in the Plan shall be construed to limit or impair the power of the Company or any Parent, Subsidiary or Affiliate to make adjustments, reclassifications, reorganizations, or changes in its capital or business structure, or to amalgamate,
merge or consolidate, liquidate, sell or transfer all or any part of its business or assets or, except as otherwise provided herein, or in a Grant Agreement, to take other actions which it deems to be necessary or appropriate. No employee,
beneficiary or other person shall have any claim against the Company or any Parent, Subsidiary or Affiliate as a result of such action. 
  

	25.	Governing Law 

 The validity, construction and
effect of the Plan, of Grant Agreements entered into pursuant to the Plan, and of any rules, regulations, determinations or decisions made by the Board or Committee relating to the Plan or such Grant Agreements, and the rights of any and all persons
having or claiming to have any interest therein or thereunder, shall be determined in accordance with applicable federal laws and the laws of the State of Maryland. Unless otherwise provided in the Award Agreement, recipients of an Award under the
Plan are deemed to submit to the exclusive jurisdiction and venue of the federal or local courts of the State of Maryland, to resolve any and all issues that may arise out of or relate to the Plan or any related Grant Agreement. The Awards under the
Plan are intended to either comply with or meet an exception from Code Section 409A and shall be so interpreted. 
  

	26.	Plan Subject to Charter and Bylaws 

 This Plan is
subject to the Certificate of Incorporation and Bylaws of the Company, as they may be in effect from time to time. 
  

	27.	Effective Date; Termination Date 

 The Plan is effective as of the date on which the Plan is approved by the stockholders of the
Company. No Award shall be granted under the Plan after the close of business on the day immediately preceding the tenth (10th) anniversary of the
effective date of the Plan. Subject to other applicable provisions of the Plan, all Awards made under the Plan prior to such termination of the Plan shall remain in effect until such Awards have been satisfied or terminated in accordance with the
Plan and the terms of such Awards. 
 Date Approved by the Board: March 12, 2007 
 Date Approved by the Stockholders: June 13, 2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]